Sipatrigine

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSipatrigine
Drug Alias Name西帕曲近SipatriginumSipatriginaBW-619C89619-C
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium channel protein type II alpha subunit blockersVoltage-gated N-type calcium channel alpha-1B subunit blockers
TargetsSodium channel protein type II alpha subunitVoltage-gated N-type calcium channel alpha-1B subunit
Therapy Area/IndicationsStroke
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsStroke

Other Information

ATC CodeN/A
Related LinksKEGG